Impact of the endocrine disruptor DEHP on adipose tissue function

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015703

Enrollment

Registered

2018-11-16

Start date

2018-11-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome E88.9 E65-E68

Interventions

Group 1: Subcutaneous adipose tissue is taken from patients undergoing planned spinal surgery. It is not an additional intervention. The adipose tissue is subsequently cultivated further as an organ

Eligibility

Sex/Gender

All

Age

45 Years to 70 Years

Inclusion criteria

Inclusion criteria: orthopedic surgeries of the spine, patient agreement declaration

Exclusion criteria

Exclusion criteria: infectious diseases (MRSA, HIV, HepB/C), diabetes, Thyroid diseases, cancer, cachexia, no patient agreement declaration

Design outcomes

Primary

Measure	Time frame
primary cell culture/ adipose tissue culture; Exposure to DEHP and isolation of mRNA and protein for expression analyses of adipocyte markers.	—

Countries

Germany

Contacts

Public ContactKristina Schädlich

Institut für Anatomie und Zellbiologie der Medizinischen Fakultät der Martin-Luther Universität Halle-Wittenberg

kristina.schaedlich@medizin.uni-halle.de03455571725

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026